Advancement in antithrombotics for stroke prevention in atrial fibrillation

Journal of Interventional Cardiac Electrophysiology

Volumn 22, Issue 2, 2008, Pages 129-137

  Umer Usman, Mohammed Haris ^a,b   Raza, Sabreen ^a   Raza, Shariq ^a   Ezekowitz, Michael ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Bioavailability; Half life; Mechanism of action; Mode of excretion

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ATI 5923; AVE 3247; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 9 INHIBITOR; DABIGATRAN; DU 176B; EMD 503982; ENOXAPARIN; HEPARIN; IDRAPARINUX; KETOCONAZOLE; KFA 1982; MACROLIDE; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PHENPROCOUMON; PLACEBO; PRT 054021; RIVAROXABAN; SSR 126517E; THROMBIN INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; TTP 889; WARFARIN; XIMELAGATRAN; YM 150;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FOOD; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; SIDE EFFECT; STROKE; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL AVAILABILITY; FACTOR IX; FACTOR XA; HALF-LIFE; HUMANS; STROKE; THROMBIN; VITAMIN K;

EID: 48949116149     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-008-9210-9     Document Type: Conference Paper

References (78)

1. R. L. Mueller S. Scheidt 1994 History of drugs for thrombotic disease. Discovery, development, and directions for the future Circulation 89 432 449
2. S. S. Shapiro 2003 Treating thrombosis in the 21st century New England Journal of Medicine 349 1762 1764
3. M. J. Fasco L. M. Principe 1982 R- and S- Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat Journal of Biological Chemistry 257 4894 4901
4. J. Hirsh J. E. Dalen D. R. Anderson L. Poller H. Bussey J. Ansell 2001 Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range Chest 119 1 Suppl 8S 21S
5. J. Ansell J. Hirsh L. Poller H. Bussey A. Jacobson E. Hylek 2004 The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl 204S 233S
6. M. Ufer 2005 Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol Clinical Pharmacokinetics 44 1227 1246 Review
7. P. Petersen G. Boysen J. Godtfredsen E. D. Andersen B. Andersen 1989 Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study Lancet 1 175 179
8. P. Petersen G. Boysen 1990 Stroke prevention in atrial fibrillation study New England Journal of Medicine 323 482
9. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators 1990 The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. New England Journal of Medicine 323 1505 1511
10. Stroke Prevention in Atrial Fibrillation Study Group 1991 Final results Circulation 84 527 539
11. S. J. Connolly A. Laupacis M. Gent R. S. Roberts J. A. Cairns C. Joyner 1991 Canadian Atrial Fibrillation Anticoagulation (CAFA) Study Journal of the American College of Cardiology 18 349 355
12. M. D. Ezekowitz S. L. Bridgers K. E. James 1992 Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators New England Journal of Medicine 327 1406 1412
13. EAFT (European Atrial Fibrillation Trial) Study Group 1993 Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342 1255 1262
14. Stroke Prevention in Atrial Fibrillation II Study Group 1994 Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study Lancet 343 687 691
15. C. Morocutti G. Amabile F. Fattapposta 1997 Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators Stroke 28 1015 1021
16. A. L. Gulløv B. G. Koefoed P. Petersen 1998 Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study Archives of Internal Medicine 158 1513 1521
17. B. S. Hellemons M. Langenberg J. Lodder 1999 Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin British Medical Journal 319 958 964
18. F Pérez-Gómez E Alegría J. Berjón J. A. Iriarte J. Zumalde A Salvador L. Mataix NASPEAF Investigators 2004 Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study Journal of the American College of Cardiology 44 1557 1566
19. Writing ACTIVE Group 2006 Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 1903 1912
20. Antithrombotic Therapy in Atrial Fibrillation Study Group 2006 [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin] Zhonghua Xin Xue Guan Bing Za Zhi 34 295 298
21. J. Mant F. D. Hobbs K. Fletcher 2007 BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial Lancet 370 493 503
22. R. G. Hart L. A. Pearce M. I. Aguilar 2007 Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Annals of Internal Medicine 146 857 867
23. T. J. Bungard W. A. Ghali K. K. Teo F. A. McAlister R. T. Tsuyuki 2000 Why do patients with atrial fibrillation not receive warfarin? Archives of Internal Medicine 160 41 46
24. B. C. Bradley K. S. Perdue K. A. Tisdel D. M. Gilligan 2000 Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center American Journal of Cardiology 85 568 572
25. V. Siguret 2007 Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy Pathologie et Biologie (Paris) 55 295 298 Article in French
26. J. Ansell J. Hirsh L. Poller H. Bussey A. Jacobson E. Hylek 2004 The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl 204S 233S
27. J. F. Carlquist B. D. Horne J. B. Muhlestein 2006 Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study Journal of Thrombosis and Thrombolysis 22 191 197
28. Bauer, K. A. (2006). New anticoagulants. Hematology (Am Soc Hematol Educ Program), 450-456, DOI.
29. B. F. Gage C. Eby P. E. Milligan G. A. Banet J. R. Duncan H. L. McLeod 2004 Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin Thrombosis and Haemostasis 91 87 94
30. S. M. Bates J. I. Weitz 2000 The mechanism of action of thrombin inhibitors Journal of Invasive Cardiology 12 Suppl F 27F 32F
31. J. I. Weitz B. Leslie M. Hudoba 1998 Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors Circulation 97 544 552
32. S. B. Olsson 2003 Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 1691 1698
33. G. W. Albers H. C. Diener L. Frison 2005 SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 690 698
34. P. T. Akins H. A. Feldman R. G. Zoble 2007 Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials Stroke 38 874 880
35. S. Kaul G. A. Diamond W. S. Weintraub 2005 Trials and tribulations of non-inferiority: the ximelagatran experience Journal of the American College of Cardiology 46 1986 1995
36. L. Wallentin M. Ezekowitz T. A. Simmers 2005 PETRO-investigators. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: a dose finding trial with comparison to warfarin European Heart Journal 26 suppl 482 Abstract
37. D. Gustafsson 2003 Oral direct thrombin inhibitors in clinical development Journal of Internal Medicine 254 322 334
38. D. Mungall 2002 BIBR-1048 Boehringer Ingelheim Current Opinion in Investigational Drugs 3 905 907
39. M. D. Ezekowitz P. A. Reilly G. Nehmiz T. A. Simmers R. Nagarakanti K. Parcham-Azad 2007 Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) American Journal of Cardiology 100 9 1419 1426
40. The Petro-ex Investigators 2006 Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation Cerebrovascular Diseases 21 suppl 4 2 Abstract
41. K. A. Bauer 2006 New anticoagulants: anti IIa vs anti Xa-is one better? Journal of Thrombosis and Thrombolysis 21 67 72
42. E. Perzborn J. Strassburger A. Wilmen 2005 In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor Thrombosis and Haemostasis 3 514 521
43. W. Mueck M. Becka D. Kubitza B. Voith M. Zuehlsdorf 2007 Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor xa inhibitor-in healthy subjects International Journal of Clinical Pharmacology and Therapeutics 45 335 344
44. D. Kubitza M. Becka G. Wensing B. Voith M. Zuehlsdorf 2005 Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects European Journal of Clinical Pharmacology 61 873 880
45. D. Kubitza M. Becka M. Zuehlsdorf W. Mueck 2007 Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects Journal of Clinical Pharmacology 47 218 226
46. D. Kubitza M. Becka M. Zuehlsdorf W. Mueck 2006 Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects Journal of Clinical Pharmacology 46 549 558
47. D. J. Pinto M. J. Orwat S. Koch 2007 Discovery of 1-(4-methoxyphenyl)-7- oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa Journal of Medicinal Chemistry 50 5339 5356
48. M. R. Lassen B. L. Davidson A. Gallus G. Pineo J. Ansell D. Deitchman 2007 The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement Thrombosis and Haemostasis 5 2368 2375
49. M. M. W. Koopman H. R. Buller 2003 Short- and long-acting synthetic pentasaccharides (minisymposium) Journal of Internal Medicine 254 335 342
50. Sanofi-aventis Press Release (2007). en.sanofi-aventis.com/Images/ 070711_idraparinux_en_tcm24-18621.pdf.
51. G. Agnelli S. Haas J. S. Ginsberg K. A. Krueger A. Dmitrienko J. T. Brandt 2007 A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement Thrombosis and Haemostasis 5 746 753
52. Iwatsuki, Y., Shigenaga, T., Moritani, Y., et al. (2006) Biochemical and pharmacological profiles of YM150, an oral direct Factor Xa inhibitor. Blood, 108, Abstract 911.
53. Overvie R&D. (2003). Yamanouchi Pharmaceutical Co Ltd. Company Presentation.
54. B. I. Eriksson A. G. Turpie M. R. Lassen 2007 ONYX study group.A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery Thrombosis and Haemostasis 5 1660 1665
55. M. U. Zafar D. A. Vorchheimer J. Gaztanaga 2007 Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber Thrombosis and Haemostasis 98 883 888
56. T. Furugohri Y. Honda C. Matsumoto 2004 Antithrombotic and hemorrhagic effects of DU-176b, a novel, potent and orally active direct Factor Xa inhibitor: a wider safety margin compared to heparins and warfarin American Society of Hematology Annual Meeting Abstract 104 1851
57. T. Fukuda C. Matsumoto Y. Honda N. Sugiyama Y. Morishima T. Shibano 2004 Antithrombotic properties of DU-176b, a novel, potent and orally active direct Factor Xa inhibitor in rat models of arterial and venous thrombosis: comparison with fondaparinux, an antithrombin dependent Factor Xa inhibitor American Society of Hematology Annual Meeting Abstract 104 1852
58. J. G. Neels B. M. van Den Berg K. Mertens 2000 Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein Blood 96 3459 3465
59. J. H. Lawson K. G. Mann 1991 Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation Journal of Biological Chemistry 266 11317 11327
60. S. S. Ahmad R. Rawala-Sheikh P. N. Walsh 1989 Platelet receptor occupancy with factor IXa promotes factor X activation Journal of Biological Chemistry 264 20012 20016
61. F. S. Chow L. J. Benincosa S. B. Sheth 2002 Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans Clinical Pharmacology and Therapeutics 71 235 245
62. C. K. Dyke S. R. Steinhubl N. S. Kleiman 2006 First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity Circulation 114 2490 2497
63. Rothlein, R., Shen, J. M., Naser, N., et al. (2005). TTP889, a Novel Orally Active Partial Inhibitor of FIXa Inhibits Clotting in Two A/V Shunt Models without Prolonging Bleeding Times. Blood, 106, Abstract 1886.
64. J. Steffel T. F. Lüscher F. C. Tanner 2006 Tissue factor in cardiovascular disease. Molecular mechanisms and clinical implications Circulation 113 722 731
65. M. Ragni P. Cirillo I. Pascucci 1996 Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis Circulation 93 1913 1918
66. L. A. Harker S. R. Hanson J. N. Wilcox A. B. Kelly 1996 Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway Haemostasis 26 Suppl 1 76 82 Review
67. J. Himber D. Kirchhofer M. Riederer T. B. Tschopp B. Steiner S. P. Roux 1997 Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function Thrombosis and Haemostasis 78 1142 1149
68. A. Pawashe P. Golino G. Ambrosio 1994 A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries Circulation Research 74 56 63
69. P. Golino M. Ragni P. Cirillo 1998 Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis Circulation Research 82 39 46
70. J. R. Riggs A. Kolesnikov J. Hendrix 2006 FVIIa inhibitors: A prodrug strategy to improve oral bioavailability Bioorganic & Medicinal Chemistry Letters 16 2224 2228
71. K. G. Zbinden U. Obst-Sander K. Hilpert 2005 Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors Bioorganic & Medicinal Chemistry Letters 15 5344 5352
72. J. Himber C. J. Refino L. Burcklen S. Roux D. Kirchhofer 2001 Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig Thrombosis and Haemostasis 85 475 481
73. Fingerle, J., Himber, J., Tschopp, T., Bunting, S., Steiner, B., & Riederer, M. A. (2001). Minimal bleeding risk after chronic application of factor VIIa inhibitor in a guinea pig model. Thrombosis and Haemostasis, Supplement:abstract #OC1766.
74. J. A. Szalony O. D. Suleymanov A. K. Salyers 2003 Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time Thrombosis Research 112 167 174
75. A. Lee G. Agnelli H. Buller 2001 Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement Circulation 104 74 78
76. R. P. Giugliano S. D. Wiviott P. H. Stone 2007 ANTHEM-TIMI-32 Investigators. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial Journal of the American College of Cardiology 49 2398 2407
77. R. A. Shirk G. P. Vlasuk 2007 Inhibitors of Factor VIIa/tissue factor Arteriosclerosis, Thrombosis, and Vascular Biology 27 1895 1900
78. R. A. Shirk G. P. Vlasuk 2007 Inhibitors of Factor VIIa/tissue factor Arteriosclerosis, Thrombosis, and Vascular Biology 27 1895 1900